曼吉费林,一种改善代谢综合征的潜在补充剂:当前状态和未来的机会
Gelin Xiang1, Sa Guo2, Nan Xing2
1State Key Laboratory of Southwestern, Chinese Medicine Resources, School of Ethnic Medicine, Chengdu, P. R. China.
The American journal of Chinese medicine
|March 27, 2024
概括
曼吉费林 (MF) 通过向参与胰岛素抵抗,肥胖和炎症的关键途径,有效治疗代谢综合征 (MetS). 进一步的研究将验证其在食品和药品中的治疗潜力.
科学领域:
- 药理学和营养保健品 药理学和营养保健品
- 代谢障碍 研究 研究 研究 代谢障碍
背景情况:
- 代谢综合征 (MetS) 是一个重大的全球健康挑战.
- 曼吉费林 (MF) 是一种天然的黄类化合物,表现出多种药理性质,具有对MetS管理的潜力.
结论:
- MF为MetS提供了一个有前途的治疗剂,在功能性食品和制药中具有潜在的应用.
- 鉴定的机制为了解MF在MetS中的作用提供了一个框架,需要进一步的实验验证.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Overview of Carbohydrate Metabolism
994
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
994
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184


